The numbers are blunt. Gland Pharma is deploying $21 million in cash to lock down a 60% stake in Novelstar Pharma Inc., a US entity that was barely a month old when the deal was structured. According to a regulatory filing released Thursday, the transaction is slated to close by October 31, 2026. It’s a direct, no-nonsense entry into the American pharmaceutical landscape, bypassing the usual slow-burn M&A negotiations for a newly formed shell.
Novelstar isn't a legacy asset with years of churn beneath it. Incorporated on September 30, it currently reports zero business activity and no turnover. Post-investment, its share capital will swell to $35 million. The structure is tight: Gland Pharma USA takes the 60% lead, while Fosun Pharma USA—sister entity to promoter Fosun Pharma Industrial—grabs the remaining 40%. This isn't just a minority bet; it’s a consolidation of Gland’s US footprint under a single, aggressive subsidiary.
There’s a red flag in the background data, though. Gland Pharma USA, the parent vehicle for this deal, saw its FY25 turnover crater to a mere $87,342, down from $483,808 in FY24. FY26 shows no turnover at all. Management is betting that the $21M injection into Novelstar will reverse this downward spiral and build a genuine revenue engine in the US.
Simultaneously, the boardroom is being reshuffled. Wenjie Zhang stepped down as a non-executive director effective October 1, citing pre-occupations. In his place, Xingli Wang, president of Fosun Pharma and head of its Global R&D Center, has been appointed. Wang brings deep R&D pedigree from Novartis and Baylor College of Medicine. This signals that the US expansion isn't just about sales; it’s about bringing innovative medicine capabilities directly to the market.
Shares closed at ₹2,866 on October 1, slipping 1.15% to lose ₹33.40. The market is watching whether this $21M commitment translates into tangible US revenue by fiscal year-end, or if it remains another speculative bet on a zero-turnover entity.